Search results
Results from the WOW.Com Content Network
After sustaining an uptrend on the markets since bottoming in February, GlaxoSmithKline (NYSE:GSK) still has an attractive profile for income and value investors. The stock’s rock-solid dividend ...
With the S&P 500 (SNPINDEX: ^GSPC) yield at just 1.2%, it has become more challenging to find companies or exchange-traded funds (ETFs) that can provide a steady and sizable stream of passive income.
In the latest trading session, GlaxoSmithKline (GSK) closed at $41.54, marking a +1.47% move from the previous day.
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. [ 4 ] [ 5 ] The company's product portfolio includes prescription medicines and vaccines .
Get breaking Business News and the latest corporate happenings from AOL. From analysts' forecasts to crude oil updates to everything impacting the stock market, it can all be found here.
The S&P 500 Dividend Aristocrats is a stock market index composed of the companies in the S&P 500 index that have increased their dividends in each of the past 25 consecutive years. It was launched in May 2005.
Dividend investing is a tried-and-true strategy for generating strong, steady returns in economies both good and bad. But as corporate America's slew of dividend cuts and suspensions over the past ...